General Information of Drug (ID: DMARIQK)

Drug Name
AT-527 Drug Info
Synonyms
AT527; SCHEMBL18061556; GTPL11295; 2241337-84-6; propan-2-yl (2S)-2-[[[(3R,4R,5R)-5-[2-amino-6-(methylamino)purin-9-yl]-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
Indication
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [1]
Cross-matching ID
PubChem CID
122527270
TTD Drug ID
DMARIQK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pyrophosphate 2- DMZQ75M Discovery agent N.A. Investigative [3]
Guanosine-5'-Triphosphate DMV2OJX Discovery agent N.A. Investigative [4]
Thiadiazolo[2,3-a]pyrimidine DMKRG2C Discovery agent N.A. Investigative [5]
T-1105 DMGPQ0Y Discovery agent N.A. Investigative [5]
Pyrimidinyl acylthiourea DM7T2VQ Discovery agent N.A. Investigative [5]
FdG DMYXA7E Discovery agent N.A. Investigative [5]
T-1106 DMPA2E9 Virus infection 1A24-1D9Z Investigative [5]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Virus RNA-dependent RNA polymerase (Viru RdRP) TTSUKYD POLG_HCVJA Inhibitor [2]

References

1 ClinicalTrials.gov (NCT04709835) Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19. U.S. National Institutes of Health.
2 AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19. Antimicrob Agents Chemother. 2021 Mar 18;65(4):e02479-20.
3 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
4 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
5 Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother. 2009 Jan;53(1):202-9.